HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Cervical Cancer.
FDA approves the first Tysabri biosimilar for MS and Crohn’s disease – Pharmaceutical Technology
Tysabri is an anti-α4 integrin monoclonal antibody disease-modifying therapy (DMT), which was first approved by the FDA in 2004. Image Credit: JHVEPhoto / Shutterstock. The
August 25, 2023